<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639482</url>
  </required_header>
  <id_info>
    <org_study_id>2009P002712</org_study_id>
    <nct_id>NCT01639482</nct_id>
  </id_info>
  <brief_title>Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram</brief_title>
  <official_title>Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using
      18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional metabolic changes associated with response to 6 weeks of citalopram treatment, using
      18-Fluorodeoxyglucose Positron Emission Tomography imaging, will be characterized (FDG PET).
      The following hypothesis will be tested: Antidepressant response or remission in depressed
      BPD patients will be associated with changes in cortical (prefrontal, parietal, premotor) and
      paralimbic (hippocampus, anterior cingulate, subgenual cingulate, posterior cingulate, and
      anterior insula) regions, consistent with SRI antidepressant response in unipolar depressed
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>rCMRglu</measure>
    <time_frame>pre and post-treatment</time_frame>
    <description>regional glucose metabolism</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <description>Patients with bipolar disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>Patients with bipolar disorder</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Bipolar Depression
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current age 18-64 years; DSM-IV diagnosis of BPD, type-I, or type-II; Enrolled in the
             Citalopram Study at Tufts Medical Center

        Exclusion Criteria:

          -  Current pregnancy, or inability to utilize contraception, The presence of any metallic
             implants, History of claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darin D Dougherty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital - East</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Darin Dougherty</investigator_full_name>
    <investigator_title>Director, Division of Neurotherapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

